Skip to Content

'
Isabelle Bedrosian, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Nellie B. Connelly Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Member of the Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

1994 Northwestern University Medical School, Chicago, IL, MD, with distinction, Medicine
1989 Tufts University, Medford, MA, BS, summa cum laude, Biology

Postgraduate Training

6/2004 Clinical Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
6/2001 Clinical Residency, Surgery, University of Pennsylvania, Philadelphia, PA

Board Certifications

2/2002 American Board of Surgery

Honors and Awards

2011-present Castle Connolly Top Doctor, Castle Connolly Medical Ltd
2009 Early Career Women's Faculty Development Award, Association of American Medical College (AAMC)
2007 Texas Federation of Business & Professional Women
2006 Faculty Research Fellowship Award, The American College of Surgeons
2005 Foundation Award, The Lehman Brothers Foundation
2002 Oncology Fellowship Award for Basic Research, James Ewing Foundation
2000 Young Investigator Award, American Association for Cancer Research (AACR)
1993 Alpha Omega Alpha, Northwestern University Medical School
1991 Biochemistry Department Sigmund S. Winton Award, Northwestern University Medical School
1989 Alumni Association Senior Award, Tufts University
1988 Alpha Xi Delta Prize Scholarship, Tufts University
1988 Phi Beta Kappa, Tufts University

Professional Memberships

Alliance for Clinical Trials in Oncology, IL
Vice Chair of the Cancer Prevention Committee, 2011-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Bloom E, Camacho TL, Gifford KA, Kirsner S, Kisling KD, Nelson CL, Mason BE, Bejarano M, Hoover S, Hunt K, Bedrosian I , Babiera G. The Importance of Multidisciplinary Collaboration Between Surgeon and Radiation Oncologist for Optimal Placement of Single-Entry Brachytherapy Catheters for Accelerated Partial Breast Irradiation. Annals of Surgical Oncology. In Press.
2. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I . Suppression of Akt-m TOR pathway-a novel component of oncogene induced DNA damage response (DDR) barrier in breast. PLOS One. e-Pub 2014.
3. Yi M, Kuerer, HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I , Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the american college of surgeons oncology group z0011 criteria applied to a contemporary patient population. J Am Coll Surg 216(1):105-13, 2013 Jan, 2013. PMID: 23122536.
4. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I , Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of Internal Mammary Lymph Node Drainage Identified by Preoperative Lymphoscintigraphy on Outcomes in Patients with Stage I to III Breast Cancer. Cancer 118(24):6287-96, 12/2012. e-Pub 5/2012. PMID: 22648744.
5. Brewster AM, Bedrosian I , Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637-43, 11/2012. e-Pub 4/2012. PMCID: PMC3478501.
6. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I . Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14(3). e-Pub 5/2012. PMID: 22621306.
7. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I , Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective Evaluation of the Nipple-Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer. Ann Surg Oncol 19(4):1137-44, 4/2012. e-Pub 10/2011. PMID: 21979111.
8. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I , Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence after Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol 19(3):901-7, 3/2012. e-Pub 8/2011. PMID: 21861223.
9. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I , Dawood S, Arun B, Albarracin CT. Invasive Paget Disease of Breast: Clinicopathologic Study of an Under-Recognized Entity in the Breast. Am J of Surg PathoL 36(9):1353-8, 2012. PMID: 22895267.
10. Bedrosian I , Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401-9, 2010 Mar 17, 2012. PMID: 20185801.
11. Bedrosian I , Nelson H. The paradox of Breast MRI: does finding occult disease make a difference. Bull Am Coll Surg 97(10):57-9, 2012 Oct, 2012. PMID: 23115888.
12. Sharma R, Bedrosian I , Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899-908, 11/2010. e-Pub 5/2010. PMID: 20443145.
13. Yi M, Hunt KK, Arun BK, Bedrosian I , Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. Cancer Prev Res (Phila) 3(8):OF1-9, 8/2010. e-Pub 7/2010. PMID: 20647335.
14. Bedrosian I , Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 116(11):2543-2548, 6/2010. PMID: 20336790.
15. Bedrosian I , Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401-409, 3/2010. e-Pub 2/2010. PMID: 20185801.
16. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I . Margin Assessment after Neoadjuvant Chemotherapy in Invasive Lobular Cancer. Am J Surg 198(3):387-91, 9/2009. e-Pub 4/2009. PMID: 19362281.
17. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I . Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115(3):651-9, 6/2009. e-Pub 12/2008. PMID: 19107593.
18. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I . Neoadjuvant chemotherapy in invasive lobular carcinoma does not improve rates of breast conservation. Ann Surg Oncol 16(6):1606-11, 6/2009. e-Pub 3/2009. PMID: 19280264.
19. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I . A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1555-62, 4/2009. PMID: 19195040.
20. Bedrosian I , Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E associated kinase activity predicts response to platinum based chemotherapy. Clin Cancer Res 13(16)(16):4800-4806, 8/2007. PMID: 17699858.

Invited Articles

1. Dominici LS, Mittendorf EA, Yu TK, Bedrosian I . Impact of breast cancer subtypes on local-regional outcomes. Current Breast Cancer Reports. In Press.

Last updated: 7/29/2014